Cesar Homero Gutiérrez‐Aguirre

Author

Universidad Autónoma de Nuevo León ORCID

Also Known As

C H Gutierrez-Aguirre, C H Gutiérrez-Aguirre, C. Gutierrez-Aguirre, C. H. Gutierrez-Aguirre, C. H. Gutiérrez-Aguirre, C. H. Gutiérrez‐Aguirre, C.H. Gutierrez-Aguirre, C.H. Gutiérrez-Aguirre, Cesar H Gutiérrez-Aguirre, Cesar H Gutiérrez-Aguirre

215

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Universidad Autónoma de Nuevo León Clínica Ruiz Hospital Universitario Dr José Eleuterio Gonzalez Mexican Social Security Institute Universidade Estadual de Campinas (UNICAMP)

About

Cesar Homero Gutiérrez‐Aguirre is an author at Universidad Autónoma de Nuevo León specializing in medicine, hematology, and transplantation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	24	698
2	Health Sciences	7	7	220
3	Blood Transplantation	5	5	127
4	Public Health	2	2	41
5	Cell Biology	1	1	45

Cesar Homero Gutiérrez‐Aguirre

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL Eduardo Magalhães Rego, Haesook T. Kim, Guillermo J. Ruíz‐Argüelles, Blood	2013	148
Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults David Gómez‐Almaguer, Miguel Ángel Herrera-Rojas, José Carlos Jaime‐Pérez, Blood	2014	99
Alemtuzumab for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease David Gómez‐Almaguer, Guillermo J. Ruíz‐Argüelles, Luz Tarín-Arzaga, Biology of Blood and Marrow Transplantation	2007	81
Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias David Gómez‐Almaguer, Manuel Solano-Genesta, Luz Tarín‐Arzaga, Blood	2010	74
Danazol as first-line therapy for aplastic anemia José Carlos Jaime‐Pérez, Perla R. Colunga‐Pedraza, Cynthia D. Gómez-Ramírez, Annals of Hematology Hematological MalignancyBone Marrow FailurePharmacologyHematologyPharmacotherapy	2011	70
High response rate to low‐dose rituximab plus high‐dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia David Gómez‐Almaguer, Luz Tarín‐Arzaga, Brizio Moreno‐Jaime, European Journal Of Haematology	2013	68
Cost Structure and Clinical Outcome of a Stem Cell Transplantation Program in a Developing Country: The Experience in Northeast Mexico José Carlos Jaime‐Pérez, Alberto Carlos Heredia-Salazar, Olga Graciela Cantú‐Rodríguez, The Oncologist	2015	62
Safety and tolerability of intrathecal delivery of autologous bone marrow nucleated cells in children with cerebral palsy: an open-label phase I trial Consuelo Mancías‐Guerra, Alma Rosa Marroquín-Escamilla, Óscar González‐Llano, Cytotherapy Regenerative MedicineCell TherapyBone Marrow FailureStem Cell TransplantationHematology	2014	58
Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? Guillermo J. Ruíz‐Argüelles, L-del-C Tarín-Arzaga, Martha L. González-Carrillo, Bone Marrow Transplantation OncologyPh-positive Cml LivingClinical TherapeuticPharmacologyPharmacotherapy	2008	55
The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study Guillermo J. Ruíz‐Argüelles, David Gómez‐Almaguer, Amelia Morales‐Toquero, Bone Marrow Transplantation Chronic PhaseHematological MalignancyTransplantationMarrow TransplantationOncology	2005	47

Page 1